1xbet 우회 Pharmaceutical Co., Ltd.

• 1xbet 우회 Japan, E Keppra^®is marketed 1xbet 우회 partial-onset seizures (including secondary generalized seizures) in patients with epilepsy and has been used in over 100,000 patients. It recently obtained an additional indication 1xbet 우회 adjunctive treatment of generalized tonic-clonic seizures.
• Seizures associated with epilepsy are classified into two types: partial-onset seizures and generalized seizures. Generalized tonic-clonic seizures, which account 1xbet 우회 60% of generalized seizures, feature a sudden loss of consciousness associated with generalized rigidity and violent convulsions.
• The Japan Epilepsy Society and the Japanese Society of Child Neurology petitioned the MHLW's Council on Unapproved Drugs and Indications with Unmet Medical Needs, calling 1xbet 우회 the development and approval of E Keppra^®1xbet 우회 adjunctive therapy 1xbet 우회 generalized tonic-clonic seizures in patients with idiopathic generalized epilepsy. Its approval is expected to contribute to the treatment of patients with these seizures.

1xbet 우회 Pharmaceutical Co., Ltd. and UCB Japan Co., Ltd. today announced that E Keppra^®was approved in Japan 1xbet 우회 an additional indication as adjunctive therapy with other anti-epileptic drugs 1xbet 우회 generalized tonic-clonic seizures in adult patients and pediatric patients aged four years and over with epilepsy showing inadequate responses to other anti-epileptic drugs. Otsuka Pharmaceutical and UCB Japan are engaged in the co-development and co-commercialization of E Keppra^®in Japan. The 1xbet 우회mulations approved 1xbet 우회 this indication include E Keppra^®Tablets 250 mg and 500 mg, E Keppra^®Dry Syrup 50%, and E Keppra^®1xbet 우회 IV Infusion 500 mg.